Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

48.41 +1.05 (+2.22%)
Official Closing Price Updated: 7:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable... 
Via TokenRing AI
Topics Artificial Intelligence
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
AnaptysBio ends its ulcerative colitis trial after rosnilimab misses key goals, focusing resources on rheumatoid arthritis and future programs. 
Via Benzinga
Looking Into GSK PLC's Recent Short Interest
 
Via Benzinga
Earnings Scheduled For October 29, 2025
 
Via Benzinga
GSK Buys Global Rights To Preclinical Cancer Therapy For $357M
Via Stocktwits
FDA Fast-Tracks 6 More Drugs - Obesity And Cancer Drugs Included
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs. 
Via Benzinga
The Fading Luster: Is the "Gold Rush Over" While Stocks Remain "Overheated"?
The financial markets are currently grappling with a potent and increasingly vocal narrative: the "gold rush is over" for commodities, particularly gold, while the stock market, especially in certain... 
Via MarketMinute
Topics Artificial Intelligence Cannabis ETFs
AI Revolutionizes Pharma Supply Chains: A New Era of Localized Resilience and Efficiency
The pharmaceutical industry is experiencing a profound and immediate transformation as Artificial Intelligence (AI) becomes a strategic imperative for localizing supply chains, fundamentally enhancing... 
Via TokenRing AI
Topics Artificial Intelligence Economy Fraud
2 High-Yield Stocks With Fresh Catalysts
Income investors can capture yields above 5% from companies executing business transformations. 
Via The Motley Fool
Topics Lawsuit
Navigating the Turbulence: Understanding Market Volatility Amidst Record Highs
As late 2025 unfolds, the global stock market presents a fascinating paradox: major U.S. indices, including the S&P 500, Dow Jones Industrial Average (NYSE: ^DJI), and Nasdaq Composite (NASDAQ: ^IXIC),... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Bonds
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026
GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2025 outlook. 
Via Benzinga
GSK Jumps After Hiked 2025 Guidance Widely Outperforms Expectations
GSK stock rose early Wednesday on strong 2025 guidance on the back of its third-quarter sales and earnings beat. 
Via Investor's Business Daily
Dow Jones Soars to New Record High Amidst Wave of Optimism, Signaling Robust Market Confidence
The Dow Jones Industrial Average (DJIA) recently achieved a significant milestone, surging by over 200 points to close at an unprecedented all-time record high in October 2025. This remarkable ascent... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free survival in Phase 3 trial. 
Via Benzinga
GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short
The company won approval for its drug, Blenrep. But it wasn't enough. 
Via Investor's Business Daily
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff. 
Via Benzinga
Healthcare’s AI Revolution: Generative Intelligence Delivers Real Returns as Agentic Systems Drive Measurable Outcomes
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements... 
Via TokenRing AI
Topics Artificial Intelligence Economy
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment
NICE recommends ViiV Healthcare's Apretude as the first injectable PrEP for HIV prevention, offering an alternative to daily oral medication. 
Via Benzinga
AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals
A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion. 
Via Benzinga
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of... 
Via MarketMinute
Topics Economy Intellectual Property Retirement
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
AnaptysBio Charts Path To Split Into Two Public Companies By 2026
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas. 
Via Benzinga
GSK’s First Female CEO Steps Down After Nearly A Decade — Retail Hopes New Leadership Can Revive Lagging Stock
Emma Walmsley’s departure comes as GSK works to strengthen its drug pipeline and offset the upcoming loss of patent protection on its top-selling HIV drug, dolutegravir. 
Via Stocktwits
Topics Intellectual Property
AstraZeneca's Strategic Listing Harmonization: A Unified Global Platform for Growth
AstraZeneca (LSE: AZN, NASDAQ: AZN) has announced a significant strategic move to harmonize its stock market listings across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York... 
Via MarketMinute
Topics Economy
Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. Luke will succeed the current CEO, Dame Emma... 
Via Benzinga
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern. 
Via Investor's Business Daily
Amgen Expands US Manufacturing Network Amid New Tariff Policy
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network. 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.